Clinical Trials GPS Highlights New Diabetes Trials; Aims to Help the Over 25 Million Individuals in U.S. Affected by Diabetes

Share Article

25.8 million children and adults in the United States—8.3% of the population—have diabetes. This equates to $116 billion in direct medical costs, and another $58 billion in indirect costs.

THE COST OF DIABETES

As shown on Clinical Trials GPS, the national cost of diabetes in the U.S. now exceeds $174 billion. This includes $116 billion in excess medical expenditures attributed to diabetes, as well as $58 billion in reduced national productivity. On Average, people diagnosed with diabetes have medical expenditures that are more than double of those who do not have diabetes.

THE COST OF DIABETES (INFOGRAPHIC)

WHO IT AFFECTS

Each year, there are roughly 2 million new cases of Diabetes in people over 20 years of age. In total, 25.8 million children and adults in the United States—8.3% of the population—have diabetes. This includes 18.8 million diagnosed and 7 million undiagnosed. It is also estimated that 79 million people are considered “prediabetes”.

Under 20 years of age: 215,000, or 0.26% of all people in this age group have diabetes. About 1 in every 400 children and adolescents has diabetes

Age 20 years or older: 25.6 million, or 11.3% of all people in this age group have diabetes

Age 65 years or older: 10.9 million, or 26.9% of all people in this age group have diabetes

Men: 13.0 million, or 11.8% of all men aged 20 years or older have diabetes
Women: 12.6 million, or 10.8% of all women aged 20 years or older have diabetes

WHAT IT COSTS

$174 billion: Total costs of diagnosed diabetes in the United States in 2007
$116 billion for direct medical costs
$58 billion for indirect costs (disability, work loss, premature mortality)

COMPLICATIONS FROM DIABETES

In 2004, heart disease was noted on 68% of diabetes-related death certificates among people aged 65 years or older.

In 2005-2008, of adults aged 20 years or older with self-reported diabetes, 67% had blood pressure greater than or equal to 140/90 mmHg or used prescription medications for hypertension.

Diabetes is the leading cause of new cases of blindness among adults aged 20–74 years, and the leading cause of kidney failure, accounting for 44% of new cases in 2008.

More than 60% of nontraumatic lower-limb amputations occur in people with diabetes.

*Data provided by the 2011 National Diabetes Fact Sheet

DIABETES CLINICAL TRIALS

Two recent diabetes clinical trials are focusing on the rising epidemic of diabetes:

Natural History Study of the Development of Type 1 Diabetes

The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to enhance their understanding of the immunologic, demographic, and metabolic characteristics of individuals at risk for developing Type 1 Diabetes.

The study is “observational” and is currently enrolling male and female individuals up to age 45. The study is being conducted at the University of Miami School of Medicine, among other facilities across the country. You can learn more about the Natural History Study of the Development of Type 1 Diabetes Trials along with some of the other clinical drug trials in Miami.

Diabetes Care in Nursing Home Residents: A Randomized Controlled Study

Nursing home residents with diabetes have higher rates of serious comorbidities and have greater activity of daily living dependencies than other residents without diabetes. In addition, persons with diabetes have higher risk of hypertension, heart disease, stroke depression, cognitive impairment, and cardiovascular mortality than individuals without diabetes.

There are a few retrospective studies in elderly patients analyzing quality of diabetes care and glycemic control adjusted for medications and presence of co-morbidities in long-term care facilities; however, no previous randomized controlled trials have demonstrated benefits of glycemic control on clinical outcome, quality of life, and rate of acute metabolic complications (hyperglycemia and hypoglycemic events) in long-term care facilities. It is not known whether the use of basal insulin is superior to treatment with sliding scale insulin (SSI) in long-term care facility residents with type 2 diabetes. The investigators propose to conduct a prospective randomized control trial comparing the efficacy and safety of the basal (glargine) insulin regimen and sliding scale regular insulin in the management of nursing home patients with T2DM.

This “interventional”, Phase 4 study is currently enrolling male and female volunteers over 60 years of age at Guillermo Umpierrez in Atlanta. You can learn more about this Diabetes Care study along with other clinical trials in Atlanta, GA.

For more information about participating in a clinical trial, please visit Clinical Trials GPS (http://www.clinicaltrialsgps.com) or call (877) 330-2919.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Longan
Visit website

Media

The Cost of Diabetes (Infographic)